PMID- 11930311
OWN - NLM
STAT- MEDLINE
DCOM- 20020516
LR  - 20111117
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 185
IP  - 8
DP  - 2002 Apr 15
TI  - Comparative analysis of CD8+ T cell responses against human cytomegalovirus 
      proteins pp65 and immediate early 1 shows similarities in precursor frequency, 
      oligoclonality, and phenotype.
PG  - 1025-34
AB  - CD8+ T cells are key effectors of the immune response against human 
      cytomegalovirus (HCMV). A number of HCMV-derived CD8+ T cell epitopes are known. 
      Using epitope prediction and subsequent testing for interferon-gamma responses by 
      the ELISPOT assay, we identified an optimal human leukocyte antigen 
      (HLA)-A*0201-restricted CD8+ T cell epitope derived from the major immediate 
      early 1 (IE-1) gene product. As many as one-third of HLA-A*0201-positive, 
      HCMV-seropositive donors make responses to this peptide (residues 316-324 
      [VLEETSVML]), which can exceed responses against a published immunodominant pp65 
      epitope (residues 495-503 [NLVPMVATV]). Major histocompatibility complex peptide 
      tetramer staining facilitated detailed phenotypic analyses and revealed 
      populations that resemble terminally differentiated effector cells (CD57+ and 
      CD28-), with considerable restriction in T cell receptor beta-chain variable 
      region use. The results confirm that, although pp65 is a major target for CD8+ T 
      cells, the IE-1 protein may itself stimulate comparable responses in some 
      persons.
FAU - Khan, Naeem
AU  - Khan N
AD  - Cancer Research UK Institute for Cancer Studies, University of Birmingham, 
      Vincent Drive, Edgbaston, Birmingham, UK B15 2TA.
FAU - Cobbold, Mark
AU  - Cobbold M
FAU - Keenan, Russell
AU  - Keenan R
FAU - Moss, Paul A H
AU  - Moss PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20020325
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antigens, Viral)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Phosphoproteins)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (cytomegalovirus matrix protein 65kDa)
RN  - 0 (immediate-early proteins, cytomegalovirus)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigens, Viral/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Genes, T-Cell Receptor beta
MH  - HLA-A Antigens/analysis
MH  - HLA-A2 Antigen
MH  - Humans
MH  - Immediate-Early Proteins/*immunology
MH  - Immunodominant Epitopes
MH  - Interferon-gamma/biosynthesis
MH  - Phenotype
MH  - Phosphoproteins/*immunology
MH  - Viral Matrix Proteins/*immunology
EDAT- 2002/04/04 10:00
MHDA- 2002/05/17 10:01
CRDT- 2002/04/04 10:00
PHST- 2001/06/11 00:00 [received]
PHST- 2001/12/05 00:00 [revised]
PHST- 2002/04/04 10:00 [pubmed]
PHST- 2002/05/17 10:01 [medline]
PHST- 2002/04/04 10:00 [entrez]
AID - JID010654 [pii]
AID - 10.1086/339963 [doi]
PST - ppublish
SO  - J Infect Dis. 2002 Apr 15;185(8):1025-34. doi: 10.1086/339963. Epub 2002 Mar 25.